drugset / Trial / NCT05959421
Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure
Phase 3
Withdrawn
University Medical Center Hamburg-Eppendorf
Bernhard Nocht Institute for Tropical Medicine · collabGerman Federal Ministry of Education and Research · collabGoethe University · collabMonipol Deutschland GmbH · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This study is a multi-center, open label, randomized phase 3b trial to assess the durability of Immunity induced by the Ebolavirus Vaccine VSV-EBOV ( with or without booster vaccination) in individuals at potential occupational risk for ebolavirus exposure
Timeline
- Start
- 2026-06
- Primary completion
- 2027-12
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ervebo | Vaccine | 7.2e+07 unknown | Intramuscular |